The biomedical campus of Heidelberg University, in close vicinity to other top research institutions, including the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), belongs to the leading cancer research centers worldwide, which provides a supportive multidisciplinary working environment and offers state-of-the-art research facilities. The Department of Surgery with the European Pancreas Center at Heidelberg University Hospital is recognized as one of the premier institutions for the diagnosis and treatment of pancreatic diseases, particularly for pancreatic cancer.
The research group of Susanne Roth MD, PhD at the Department of Surgery at Heidelberg University Hospital, Germany, offers a
PhD position in cancer immunology/bioinformatics
Our newly established, international and enthusiastic research group is a member of the excellence initiative of the German Cancer Aid (Max-Eder-Program) that focuses on translational pancreatic/gastrointestinal cancer research and is integrated in the European Pancreas Center (https://www.europaeisches-pankreaszentrum.de/extrainfo/international-office/) within an inspiring dynamic research environment in close collaboration with the group of Mathias Heikenwälder at the DKFZ (https://www.dkfz.de/en/chronische-entzuendung-und-krebs/index.php) and Wolfgang Huber at the EMBL (https://www.embl.de/research/units/genome_biology/huber/). Our group studies how inflammatory responses influence gastrointestinal carcinogesis, especially in the pancreas. Specifically, we are interested in the detailed characterization of immune cell types and their interactions within the tumor microenvironment, understanding the molecular mechanisms that affect tumor cell growth, invasiveness and lead to therapy resistance in a translational research framework. To resolve heterogeneity in cell populations we apply single-cell technologies, combined with imaging and bioinformatic approaches. Our research findings are largely obtained from the direct study of patient-derived samples. An improved understanding of the immune signaling pathways that contribute to tumorigenesis could enable the development of novel immunotherapeutic strategies against these devastating diseases. In addition, we develop therapy response prediction methods for individualized treatment strategies that could be immediately administered clinically.
The candidate will join a multidisciplinary team within a stimulating atmosphere with excellent scientific working conditions, access to state-of-the-art instrumentation at the Heidelberg University biomedical campus, networks with experienced scientists and further training opportunities. Starting from January 1st 2020 we offer a PhD position for (initially) one year with the possibility of extension for 2-3 more years. Salary is paid according to the German public service scale based on candidates’ background and experience (TV-L).
- MSc (or equivalent) in bioinformatics, biology, biotechnology, biochemistry, medicine, or a related field with preferentially a solid background in immunology, systems or cancer biology.
- Experiences in imaging methods, image analysis, single cell analysis (e.g. scRNAseq, CyTOF), integrated analysis of large/high-dimensional data sets, applications of mathematical models and machine learning are favourable.
- Ability to work independently and collaboratively with colleagues from different disciplines
- Creative and innovative thinking paired with strong analytical skills
- Proactive attitude and enthusiasm for research
- Fluent written and spoken English
Candidates are invited to send their application as soon as possible, preferably by e-mail, directly to firstname.lastname@example.org
Please send a single pdf file including a motivation letter stating research and career interests, expected availability date, CV, certificates, and at least one expressive letter of reference.